NEW YORK--(BUSINESS WIRE)--Metropolitan Bank Holding Corp. (the "Company†) (NYSE: MCB), the holding company for Metropolitan Commercial Bank (the "Bank†), a full-service commercial bank based in New York City, announced that it will host an investor day on Tuesday, March 3, 2026, from 9:30 a.m. to 1:30 p.m. ET. MCB has earned national recognition for its financial performance, innovation, and strategic growth. The Bank was named one of Newsweek's Best Regional Banks in 2024 and 2025 and ranked by the In ...

Core Insights - Ironwood Pharmaceuticals reported its fourth quarter and full year 2025 results, highlighting significant developments in its product LINZESS and the advancement of apraglutide [1][2]. Financial Performance - Total revenue for Q4 2025 was $47.7 million, down from $90.5 million in Q4 2024. For the full year 2025, total revenue was $296.2 million, compared to $351.4 million in 2024 [3][11]. - GAAP net loss for Q4 2025 was $2.3 million, or $(0.01) per share, compared to a net income of $2.3 million, or $0.01 per share, in Q4 2024. For the full year 2025, GAAP net income was $24.0 million, or $0.15 per share, compared to $0.9 million, or $0.01 per share, in 2024 [3][40]. - Adjusted EBITDA for Q4 2025 was $10.9 million, down from $37.3 million in Q4 2024. For the full year 2025, adjusted EBITDA was $138.1 million, compared to $129.4 million in 2024 [3][12]. Product Performance - LINZESS achieved 11% year-over-year demand growth in 2025, treating over 5.7 million unique patients since its launch. However, U.S. net sales for LINZESS were $163.2 million in Q4 2025, a 27% decrease from $223.0 million in Q4 2024, and $864.5 million for the full year 2025, a 6% decrease from $916.3 million in 2024 [2][8][9]. - Total LINZESS prescription demand in Q4 2025 was 63 million capsules, a 13% increase compared to Q4 2024, and 234 million capsules for the full year 2025, an 11% increase compared to 2024 [8][9]. Strategic Initiatives - The company plans to focus on maximizing LINZESS, advancing apraglutide, and delivering sustained profits and cash flows in 2026. The financial guidance for 2026 includes expected U.S. LINZESS net sales of $1.125 - $1.175 billion and adjusted EBITDA exceeding $300 million [2][13]. - Apraglutide is being developed for short bowel syndrome patients dependent on parenteral support, with a Phase 3 clinical trial (STARS-2) expected to initiate in Q2 2026 [8][10]. Corporate Developments - In December 2025, Ironwood entered into a settlement agreement with Ferring International Center S.A., agreeing to pay $12.5 million, with $7.5 million paid in December 2025 and the remaining $5.0 million due by December 31, 2026 [10].

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Accessibility Statement] Skip NavigationROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this ...

Market Analysis by covering: NVIDIA Corporation, Micron Technology Inc. Read 's Market Analysis on Investing.com ...

John David Escobar/iStock via Getty Images Listen below or on the go via Apple Podcasts and Spotify UBS hikes worst-case private credit default view to 15% on AI fears. (00:14) AMC Entertainment (AMC) flags opportunity to close underperforming theaters amid attendance, screen declines. (01:30) Trump orders tech giants to power their own AI data centers under ‘rate protection’ pledge. (02:36) This is an abridged transcript. Strategists at UBS Group (UBS) now warn that default rates in private credit c ...

Key Takeaways Investors say AI agent wallets are arriving faster than frameworks for liability and attribution. U.S. e-transactions law recognizes “electronic agents,” but modern autonomy raises harder questions about control and fault. OECD AI principles emphasize accountability and traceability by role, a model that maps to agent-wallet oversight. Crypto investors are warning that AI agents with crypto wallets are moving from novelty to early deployment, creating legal and compliance risks befor ...

Thailand’s new vehicle market rebounded by almost 54% to 73,936 units in January 2026 from weak year-earlier sales of 48,092 units, according to the latest data released by the Federation of Thai Industries (FTI). January was the tenth consecutive month of growth for the country’s vehicle market, following two years of sharp declines as the country’s highly indebted consumers and small businesses struggled to access financing after banks tightened lending rules. Economic growth in the country accelerated ...

Nuclear Giant Constellation Closes Calpine Deal While Retail Investors Lose Faith - 24/7 Wall St.[S&P 5006,912.40 +0.31%][Dow Jones49,320.40 +0.32%][Nasdaq 10025,077.80 +0.39%][Russell 20002,667.81 +0.61%][FTSE 10010,783.30 +0.65%][Nikkei 22559,655.30 +2.98%][Investing]# Nuclear Giant Constellation Closes Calpine Deal While Retail Investors Lose Faith### Quick ReadConstellation Energy (CEG) is down 17% year-to-date to $293. Retail investor sentiment dropped from 54.7 to 41.1.Constellation closed the Calpine ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program conducted i ...

States, Taiwan and the United Kingdom. Garmin, inReach, fnix, GPSMAP, quatix and Tread are registered trademarks, Garmin Messenger and LiveTrack are trademarks and Garmin Response is a service mark of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.Notice on Forward-Looking Statements:This release includes forward-looking statements regarding Garmin Ltd. and its business. Such sta ...